ASH 2010: Brentuximab Showing Promise as Hodgkin Lymphoma Therapy

Bonnie Gillis
Published: Tuesday, Mar 08, 2011
An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a phase II study of younger patients with relapsed or refractory Hodgkin lymphoma (HL) who had no other treatment options, investigators revealed at the 52nd American Society of Hematology Annual Meeting and Exposition. Based on results of this pivotal trial, Seattle Genetics and Millennium plan to seek regulatory approval of brentuximab in the United States and Europe as a treatment for HL and anaplastic large-cell lymphoma (ALCL). The companies expect to file in the first quarter of 2011.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication